Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM-H014
- Development stage
- Phase 2
- Lead developer
- Changchun Intellicrown Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IMM-H014 is a novel small molecule drug under development for the treatment of metabolic-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). It is an original compound with a collateral phenyl structure and has demonstrated anti-inflammatory activity as well as the ability to increase insulin sensitivity in preclinical studies. IMM-H014 was designed based on bicyclol, a hepatoprotective agent approved in China for chronic hepatitis; however, IMM-H014 exhibits improved pharmacokinetic properties and enhanced liver-protective effects compared to bicyclol. The drug is being developed in extended-release tablet formulations and is currently undergoing phase 1 clinical trials in China. Its precise mechanism of action involves modulation of nuclear factor pathways but remains incompletely characterized[1][3][4][6][8].
- Other names
- methyl 7,7′-dimethoxy-5-(morpholinomethyl)-[4,4′-bibenzo[d][1,3]dioxole]-5-carboxylate methanesulfonate
Beyond the preview
Go deeper on IMM-H014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM-H014.